

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/501,060
<b>Filing Date</b>	July 9, 2004
<b>First Named Inventor</b>	W.K. Hagmann et al.
Group Art Unit	
Examiner Name	
<b>Attorney Docket Number</b>	20991P

1 of 3

Attorney Docket Number 20991P

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
			EP 0 658 546		Sanofi	06/21/1995
			WO 97/29079		Japan Tobacco Inc.	08/14/1997
			WO 98/41519		SmithKline Beecham Corporation	09/24/1998
			WO 98/31227		SmithKline Beecham Corporation	07/23/1998
			WO 98/43636		Sanofi	10/08/1998
			WO 98/43635		Sanofi	10/08/1998
			WO 99/02499		Japan Tobacco Inc.	01/21/1999
			WO 01/32663		Sanofi-Synthelabo	05/10/2001
			WO 01/58450		Sanofi-Synthelabo	08/16/2001
			WO 01/58869		Bristol-Myers Squibb Company	08/16/2001

Date  
Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

## INFORMATION DISCLOSURE

(use as many sheets as necessary)

Sheet

2

of

3

<b>Application Number</b>	10/501,060
---------------------------	------------

10/501,060

<b>Filing Date</b>	July 9, 2004
--------------------	--------------

July 9, 2004

<b>First Named Inventor</b>	W.K. Hagmann et al.
-----------------------------	---------------------

W.K. Hagmann et al.

## Group Art Unit

Examiner Name

Attorney Docket Number	20991P
------------------------	--------

20991P

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
			WO 01/70700	Solvay Pharmaceuticals B.V.	09/27/2001
			WO 01/85092	Sanofi-Synthelabo	11/15/2001
			WO 02/28346	Aventis Pharma S.A.	04/11/2002
			WO 02/076949	Solvay Pharmaceuticals B.V.	10/03/2002
			WO 03/026648	Solvay Pharmaceuticals B.V.	04/03/2003
			WO 03/027076	Solvay Pharmaceuticals B.V.	04/03/2003
			WO 03/027069	Bayer Pharmaceuticals Corporation	04/03/2003
			WO 03/040107	Bayer Pharmaceuticals Corporation	05/15/2003
			WO 03/084930	Sanofi-Synthelabo	10/16/2003
			WO 2004/034968	The Regents of the Univ. of California	04/29/2004

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

## INFORMATION DISCLOSURE

(use as many sheets as necessary)

<b>Application Number</b>	10/501,060
---------------------------	------------

<b>Filing Date</b>	July 9, 2004
--------------------	--------------

<b>First Named Inventor</b>	W.K. Hagmann et al.
-----------------------------	---------------------

Group Art Unit

Examiner Name

Attorney Docket Number	20991P
------------------------	--------

## NON PATENT LITERATURE DOCUMENTS

[illegible]

Date Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder). Merck & Co., Inc., 09/05/2003

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: W.K. HAGMANN et al.



Serial No. 10/501,060

Filed: July 9, 2004

For: SUBSTITUTED IMIDAZOLES AS CANNABINOID  
RECEPTOR MODULATORS

Art Unit: \_\_\_\_\_

Examiner: \_\_\_\_\_

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK &amp; CO., INC.

By [Signature] Date 10/1/2004

**INFORMATION DISCLOSURE STATEMENT**

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:


RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: CATHERINE D. FITCH

Attorney \_\_\_\_\_ For Applicant(s)

Reg. No. 36,502

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-4283

Date: Oct 1, 2004